Acid Reducers

Drugs which actively reduce the hydronium concentration of the gastric system. Includes proton pump inhibitors and H2 antagonist drugs.
DrugDrug NameDrug Indication
DB00213Pantoprazole **Pantoprazole Injection**: **Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis** Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_.[FDA label] **Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome** Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.[FDA label] **Pantoprazole delayed-release oral suspension**: **Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)** Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined.[F3202] **Maintenance of healing of erosive esophagitis** Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.[F3202] **Pathological hypersecretory conditions including Zollinger-Ellison syndrome** Indicated for the long-term treatment of the above conditions.[F3202]
DB00338OmeprazoleOmeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes: • Treatment of active duodenal ulcer in adults • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults • Treatment of active benign gastric ulcer in adults • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older • Pathologic hypersecretory conditions in adults
DB00448LansoprazoleLansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label] It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label] Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label] Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]
DB00736EsomeprazoleEsomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome.
DB01129RabeprazoleFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
DB05351DexlansoprazoleDexlansoprazole is indicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).
DB13762DexrabeprazoleNot Available
DB00501CimetidineFor the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.
DB00585NizatidineFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.
DB00863RanitidineThis drug is used alone or with concomitant antacids for the following conditions [FDA label]: **Duodenal ulcer** Treatment of active duodenal ulcer (short-term), maintenance therapy of duodenal ulcers after healing (reduced dose) **Pathological hypersecretion of gastric acid** Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions causing gastric acid hypersecretion **Gastric ulcer** Short term treatment of active gastric ulcer (benign), maintenance of healing after gastric acid ulcer therapy (reduced dose) **Other conditions**: Treatment of GERD symptoms (symptoms usually improve within 24 hours), treatment of erosive esophagitis (endoscopically diagnosed) and maintenance of healing [FDA label]
DB00927FamotidineFor the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
DB01142DoxepinOral doxepin is approved for the following indications: - Treatment of depression and/or anxiety.[A177163] - Treatment of depression and/or anxiety associated with different conditions, including alcoholism, organic disease and manic-depressive disorders.[T249] - Treatment of psychotic depressive disorders with associated anxiety.[T249] - Treatment of involutional depression.[T249] - Treatment of manic-depressive disorder.[T249] - Treatment of insomnia characterized by difficulties with sleep maintenance.[A177163] Topical doxepin is also approved for short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis, pruritus or lichen simplex chronicus.[T249] Off-label, doxepin is used topically for the management of neuropathic pain.[A177172] Depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities. This condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environment.[L5980] Anxiety is a normal reaction of the body towards a normal danger. When the anxious state is exacerbated or appears on situations without danger, it is defined as an anxiety disorder. This disorders can appear in different forms such as phobias, panic, obsessive-compulsive disorder and post-traumatic stress disorder.[L5983] Insomnia is a sleep disorder that directly affects the quality of life of the individual. It is characterized by the complication either to fall asleep or to stay asleep. This condition can be occasional or chronic.[L5986] Pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch. It can be localized or generalized and it can appear in an acute or chronic manner.[L5989] Neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptors.[L5992]
DB00751EpinastineFor the prevention of itching associated with allergic conjunctivitis.
DB06216AsenapineUsed for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination.
DB00940MethanthelineFor the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children.
DB08805MetiamidePotential in the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.
DB08806Roxatidine acetateFor the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers. Also for prophylaxis of recurrent gastric and duodenal ulcers
DB01069PromethazineFor the treatment of allergic disorders, and nausea/vomiting.
DrugDrug NameTargetType
DB00213PantoprazolePotassium-transporting ATPase alpha chain 1target
DB00213PantoprazoleCytochrome P450 2C19enzyme
DB00213PantoprazoleCytochrome P450 3A4enzyme
DB00213PantoprazoleMultidrug resistance protein 1transporter
DB00213PantoprazoleATP-binding cassette sub-family G member 2transporter
DB00213PantoprazoleSolute carrier family 22 member 8transporter
DB00213PantoprazoleN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB00338OmeprazolePotassium-transporting ATPase alpha chain 1target
DB00338OmeprazoleCytochrome P450 2C19enzyme
DB00338OmeprazoleCytochrome P450 3A4enzyme
DB00338OmeprazoleCytochrome P450 2C9enzyme
DB00338OmeprazoleCytochrome P450 1A2enzyme
DB00338OmeprazoleCanalicular multispecific organic anion transporter 2transporter
DB00338OmeprazoleMultidrug resistance protein 1transporter
DB00338OmeprazoleATP-binding cassette sub-family G member 2transporter
DB00338OmeprazoleCytochrome P450 1A1enzyme
DB00338OmeprazoleCytochrome P450 1B1enzyme
DB00338OmeprazoleCytochrome P450 2C18enzyme
DB00338OmeprazoleCytochrome P450 2C8enzyme
DB00338OmeprazoleCytochrome P450 2D6enzyme
DB00338OmeprazoleAryl hydrocarbon receptortarget
DB00448LansoprazolePotassium-transporting ATPase alpha chain 1target
DB00448LansoprazoleCytochrome P450 2C19enzyme
DB00448LansoprazoleCytochrome P450 2C9enzyme
DB00448LansoprazoleCytochrome P450 3A4enzyme
DB00448LansoprazoleMultidrug resistance protein 1transporter
DB00448LansoprazoleATP-binding cassette sub-family G member 2transporter
DB00448LansoprazoleCytochrome P450 1A1enzyme
DB00448LansoprazoleCytochrome P450 1B1enzyme
DB00448LansoprazoleCytochrome P450 2C18enzyme
DB00448LansoprazoleCytochrome P450 2C8enzyme
DB00448LansoprazoleCytochrome P450 2D6enzyme
DB00448LansoprazoleMicrotubule-associated protein tautarget
DB00448LansoprazoleSolute carrier family 22 member 8transporter
DB00448LansoprazoleSolute carrier family 22 member 1transporter
DB00448LansoprazoleSolute carrier family 22 member 2transporter
DB00448LansoprazoleSolute carrier family 22 member 3transporter
DB00736EsomeprazolePotassium-transporting ATPase alpha chain 1target
DB00736EsomeprazoleCytochrome P450 2C19enzyme
DB00736EsomeprazoleCytochrome P450 3A4enzyme
DB00736EsomeprazoleN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB00736EsomeprazoleMultidrug resistance protein 1transporter
DB00736EsomeprazoleSolute carrier family 22 member 8transporter
DB01129RabeprazolePotassium-transporting ATPase alpha chain 1target
DB01129RabeprazoleCytochrome P450 3A4enzyme
DB01129RabeprazoleCytochrome P450 2C19enzyme
DB01129RabeprazoleATP-binding cassette sub-family G member 2transporter
DB01129RabeprazoleCytochrome P450 1A1enzyme
DB01129RabeprazoleCytochrome P450 1A2enzyme
DB01129RabeprazoleCytochrome P450 2C9enzyme
DB01129RabeprazoleCytochrome P450 2D6enzyme
DB01129RabeprazoleCytochrome P450 2C8enzyme
DB05351DexlansoprazolePotassium-transporting ATPase alpha chain 1target
DB05351DexlansoprazoleCytochrome P450 2C19enzyme
DB05351DexlansoprazoleCytochrome P450 3A4enzyme
DB05351DexlansoprazolePotassium-transporting ATPase subunit betatarget
DB05351DexlansoprazoleN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB13762DexrabeprazoleCytochrome P450 2C19enzyme
DB00501CimetidineHistamine H2 receptortarget
DB00501CimetidineCytochrome P450 1A2enzyme
DB00501CimetidineCytochrome P450 2D6enzyme
DB00501CimetidineCytochrome P450 2C19enzyme
DB00501CimetidineCytochrome P450 3A4enzyme
DB00501CimetidineCytochrome P450 3A5enzyme
DB00501CimetidineMultidrug resistance protein 1transporter
DB00501CimetidineSolute carrier family 22 member 2transporter
DB00501CimetidineSolute carrier family 22 member 1transporter
DB00501CimetidineSolute carrier family 22 member 3transporter
DB00501CimetidineSolute carrier family 22 member 5transporter
DB00501CimetidineSolute carrier family 22 member 6transporter
DB00501CimetidineSolute carrier family 22 member 8transporter
DB00501CimetidineMultidrug and toxin extrusion protein 1transporter
DB00501CimetidineSolute carrier family 22 member 4transporter
DB00501CimetidineSolute carrier family 22 member 11transporter
DB00501CimetidineSolute carrier family 22 member 7transporter
DB00501CimetidineCytochrome P450 11B1, mitochondrialenzyme
DB00501CimetidineCytochrome P450 2C8enzyme
DB00501CimetidineCytochrome P450 2C9enzyme
DB00501CimetidineCytochrome P450 2E1enzyme
DB00501CimetidineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00501CimetidineDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB00501CimetidineBile salt export pumptransporter
DB00501CimetidineMultidrug and toxin extrusion protein 2transporter
DB00585NizatidineHistamine H2 receptortarget
DB00585NizatidineMultidrug resistance protein 1transporter
DB00585NizatidineCholinesteraseenzyme
DB00863RanitidineHistamine H2 receptortarget
DB00863RanitidineCytochrome P450 1A2enzyme
DB00863RanitidineCytochrome P450 2D6enzyme
DB00863RanitidineSolute carrier family 22 member 1transporter
DB00863RanitidineMultidrug resistance protein 1transporter
DB00863RanitidineSolute carrier family 22 member 8transporter
DB00863RanitidineCytochrome P450 3A4enzyme
DB00863RanitidineAcetylcholinesterasetarget
DB00863RanitidineSolute carrier family 22 member 2transporter
DB00863RanitidineCholinesterasetarget
DB00927FamotidineHistamine H2 receptortarget
DB00927FamotidineSolute carrier family 22 member 2transporter
DB00927FamotidineSolute carrier family 22 member 8transporter
DB01142DoxepinSodium-dependent serotonin transportertarget
DB01142DoxepinSodium-dependent noradrenaline transportertarget
DB01142DoxepinHistamine H1 receptortarget
DB01142DoxepinHistamine H2 receptortarget
DB01142DoxepinCytochrome P450 2D6enzyme
DB01142DoxepinMuscarinic acetylcholine receptor M1target
DB01142DoxepinMuscarinic acetylcholine receptor M2target
DB01142DoxepinMuscarinic acetylcholine receptor M3target
DB01142DoxepinMuscarinic acetylcholine receptor M4target
DB01142DoxepinMuscarinic acetylcholine receptor M5target
DB01142DoxepinAlpha-1A adrenergic receptortarget
DB01142Doxepin5-hydroxytryptamine receptor 1Atarget
DB01142Doxepin5-hydroxytryptamine receptor 2Atarget
DB01142DoxepinCytochrome P450 2C19enzyme
DB01142DoxepinCytochrome P450 2C9enzyme
DB01142DoxepinCytochrome P450 1A2enzyme
DB01142DoxepinMultidrug resistance protein 1transporter
DB01142Doxepin5-hydroxytryptamine receptor 2Btarget
DB01142Doxepin5-hydroxytryptamine receptor 2Ctarget
DB01142DoxepinAlpha-1B adrenergic receptortarget
DB01142DoxepinAlpha-1D adrenergic receptortarget
DB01142DoxepinCytochrome P450 3A4enzyme
DB01142Doxepin5-hydroxytryptamine receptor 6target
DB01142DoxepinHistamine H4 receptortarget
DB01142DoxepinPotassium voltage-gated channel subfamily H member 2target
DB01142DoxepinSerum albumincarrier
DB01142DoxepinAlpha-1-acid glycoprotein 1carrier
DB00751EpinastineHistamine H1 receptortarget
DB00751EpinastineHistamine H2 receptortarget
DB00751EpinastineAlpha-1A adrenergic receptortarget
DB00751EpinastineAlpha-2A adrenergic receptortarget
DB00751Epinastine5-hydroxytryptamine receptor 2Atarget
DB00751Epinastine5-hydroxytryptamine receptor 7target
DB00751EpinastineMultidrug resistance protein 1transporter
DB00751EpinastineCytochrome P450 2B6enzyme
DB00751EpinastineCytochrome P450 2D6enzyme
DB00751EpinastineCytochrome P450 3A4enzyme
DB06216Asenapine5-hydroxytryptamine receptor 1Atarget
DB06216Asenapine5-hydroxytryptamine receptor 1Btarget
DB06216Asenapine5-hydroxytryptamine receptor 2Atarget
DB06216Asenapine5-hydroxytryptamine receptor 2Btarget
DB06216Asenapine5-hydroxytryptamine receptor 2Ctarget
DB06216Asenapine5-hydroxytryptamine receptor 6target
DB06216Asenapine5-hydroxytryptamine receptor 7target
DB06216AsenapineAlpha-2A adrenergic receptortarget
DB06216AsenapineAlpha-2B adrenergic receptortarget
DB06216AsenapineAlpha-2C adrenergic receptortarget
DB06216AsenapineAlpha-1A adrenergic receptortarget
DB06216AsenapineD(1A) dopamine receptortarget
DB06216AsenapineD(2) dopamine receptortarget
DB06216AsenapineD(3) dopamine receptortarget
DB06216AsenapineD(4) dopamine receptortarget
DB06216AsenapineHistamine H1 receptortarget
DB06216AsenapineHistamine H2 receptortarget
DB06216AsenapineCytochrome P450 1A2enzyme
DB06216AsenapineCytochrome P450 2D6enzyme
DB06216Asenapine5-hydroxytryptamine receptor 5Atarget
DB06216AsenapineUDP-glucuronosyltransferase 1-4enzyme
DB06216AsenapineCytochrome P450 3A4enzyme
DB06216AsenapineBeta-1 adrenergic receptortarget
DB06216AsenapineBeta-2 adrenergic receptortarget
DB00940MethanthelineMuscarinic acetylcholine receptor M1target
DB00940MethanthelineHistamine H2 receptortarget
DB08805MetiamideHistamine H2 receptortarget
DB08806Roxatidine acetateHistamine H2 receptortarget
DB01069PromethazineD(2) dopamine receptortarget
DB01069PromethazineHistamine H1 receptortarget
DB01069PromethazineMuscarinic acetylcholine receptor M4target
DB01069PromethazineMuscarinic acetylcholine receptor M1target
DB01069PromethazineMuscarinic acetylcholine receptor M5target
DB01069PromethazineAlpha-1A adrenergic receptortarget
DB01069Promethazine5-hydroxytryptamine receptor 2Atarget
DB01069PromethazineMuscarinic acetylcholine receptor M2target
DB01069PromethazineMuscarinic acetylcholine receptor M3target
DB01069PromethazineCalmodulintarget
DB01069PromethazineCytochrome P450 2D6enzyme
DB01069PromethazineCytochrome P450 2B6enzyme
DB01069PromethazineMultidrug resistance protein 1transporter
DB01069PromethazineCytochrome P450 2C9enzyme
DB01069PromethazineHistamine H2 receptortarget